Recombinant Human c-Abl His-tag Protein, CF

Catalog #: 11091-AL Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11091-AL-020

Recombinant Human c‑Abl His-tag Protein SDS-PAGE.

1 Image

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human c-Abl His-tag Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to phosphorylate the Abl peptide substrate EAIYAAPFAKKK.
The specific activity is >200 pmol/min/μg, as measured under the described conditions.

Source

E. coli-derived human c-Abl protein
Gly227-Gln513, with an N-terminal Met and 6-His tag

Accession #

P00519.4

N-terminal Sequence
Analysis

Met

Predicted Molecular Mass

34 kDa

SDS-PAGE

33-35 kDa, under reducing conditions

Product Datasheets

11091-AL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11091-AL

Formulation	Supplied as a 0.2 μm filtered solution in Tris, NaCl, TCEP and Glycerol.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

Materials

Universal Kinase Activity Kit (Catalog # EA004)
10X Assay Buffer (supplied in kit): 250 mM HEPES, 1.5 M NaCl, 100 mM MgCl2, 100 mM CaCl2, pH 7.0
Recombinant Human ABL-1 (rhABL-1) (Catalog # 11091-AL)
Substrate: Abltide peptide (SignalChem, Catalog # A02-58), 1 mg/mL stock in 20 mM Tris, pH 7.5
96-well Clear Plate (Catalog # DY990)
Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent

Prepare 1X Assay Buffer by diluting 10X stocks 10 fold with deionized water.
Dilute 1 mM Phosphate Standard provided by the Universal Kinase Activity Kit by adding 40 µL of the 1 mM Phosphate Standard to 360 µL of 1X Assay Buffer for a 100 µM stock. This is the first point of the standard curve.
Complete the standard curve by performing six one-half serial dilutions of the 100 µM Phosphate stock using 1X Assay Buffer. The standard curve has a range of 0.078 to 5 nmol per well.
Prepare Reaction Mixture containing 0.4 mM ATP (supplied in kit) and 0.2 mg/mL Abltide peptide in 1X Assay Buffer.
Dilute rhABL-1 to 33.35 ng/µL in 1X Assay Buffer.
Dilute Coupling Phosphatase 4 (supplied in kit) to10 ng/µL in 1X Assay Buffer.
Load 50 µL of each dilution of the standard curve into a plate. Include a curve blank containing 50 µL of 1X Assay Buffer.
Load 15 µL of the 33.35 ng/µL rhABL-1 into empty wells of the same plate as the curve. Include a Control containing 15 µL of 1X Assay Buffer.
Add 10 µL of 10 ng/µL Coupling Phosphatase 4 to wells containing enzyme and Control, excluding the standard curve.
Add 25 µL of Reaction Mixture to the wells, excluding the standard curve.
Incubate sealed plate at room temperature for 10 minutes.
Add 30 µL of the Malachite Green Reagent A to all wells. Mix briefly.
Add 100 µL of deionized water to all wells. Mix briefly.
Add 30 µL of the Malachite Green Reagent B to all wells. Mix and incubate for 20 minutes at room temperature.
Read plate at 620 nm (absorbance) in endpoint mode.
Calculate specific activity:

Specific Activity (pmol/min/µg) =	Phosphate released* (nmol) x (1000 pmol/nmol)
	Incubation time (min) x amount of enzyme (µg)

*Derived from the phosphate standard curve using linear or 4-parameter fitting and adjusted for Control.
** The coupling rate is 0.475 under these conditions. Per Reaction:

rhABL-1: 0.5 µg
Coupling Phosphatase 4: 0.1 µg
ATP: 0.2 mM
Abltide peptide: 5 µg

Scientific Data

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human c‑Abl His-tag Protein (Catalog # 11091-AL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at ~33-35 kDa.

Reconstitution Calculator

Background: c-Abl

Tyrosine protein kinase ABL1 (Abelson murine leukemia viral oncogene homolog 1) is a ubiquitously expressed, magnesium-dependent, cytosolic member of the ABL subfamily of non-receptor protein tyrosine kinases (1). Human nonreceptor tyrosine kinases share a conserved domain structure that contributes to activity regulation and substrate specificity in many key processes linked to cell growth and survival (2-4). In addition, ABL1 contains domains unique to the ABL1 paralog that enable its function in DNA binding and DNA-damage response. ABL1 is composed of an N-terminal glycine myristoyl group that blocks the surface pocket of the kinase domain, a cap that stabilizes an inactive conformation, SH3 and SH2 domains that impose a locked inactive state, a protein kinase region, three nuclear localization signals, a DNA-binding region, and C-terminal nuclear export signal motifs, and actin F-binding domain (5-9). Activity is regulated through disruption of autoinhibitory interactions and several phosphorylation events that increase or decrease activity or promote function through stabilization (4). The SH2 domain contributes to both catalytic activity and target site specificity as has been shown with domain swapping (10). In chronic myelogenous, acute myeloid, and acute lymphoblastic leukemias, ABL1 is fused to BCR gene, resulting in deletion of the regulatory domains and production of a constitutively active tyrosine kinase (11). Several mutations in ABL1 lead to misregulation of activity in a variety of cancers (12). ABL1 kinase inhibition is used for therapeutic treatment in leukemic cancers and requires further development of drugs to address ABL1-mutation conferred resistance (12,13).

References

Sefton, B.M. et al. (1981) Proc. Natl. Acad. Sci. USA 78:1552.
Bradley, W.D. and A.J. Koleske (2009) J. Cell Sci. 122:3441.
Gu, J.J. et al. (2009) Immunol. Rev. 228:170.
Colicelli, J. (2010) Sci. Signal. 14:139.
Wen, S.T. et al. (1996) EMBO J. 15:1853.
Taagepera, S. et al. (1998) Proc. Natl. Acad. Sci. USA 95:7457.
Pluk, H. et al. (2002) Cell. 108:247.
Hantschel, O. et al. (2003) Cell. 112:845.
Nagar, B. et al. (2006) Mol. Cell. 21:787.
Filippakopoulos, P. et al. (2008) Cell. 134:793.
Shtivelman, E. et al. (1986) Cell. 47:277.
Wang, J. and A.M. Pendergast. (2015) Trends Cancer 1:110.
Al Hamad, M. (2021) F1000Res. 10:1288.

Long Name

Abelson Murine Leukemia Viral Oncogene Homolog 1

Entrez Gene IDs

25 (Human); 11350 (Mouse); 311860 (Rat)

Alternate Names

Abelson murine leukemia viral oncogene homolog 1; ABL; ABL1; bcr/abl; BCR-ABL1; c-abl oncogene 1, non-receptor tyrosine kinase; c-abl oncogene 1, receptor tyrosine kinase; cAbl; c-Abl; EC 2.7.10; EC 2.7.10.2; JTK7; JTK7bcr/abl; p150bcr/c-abl oncogene protein; Proto-oncogene c-Abl; proto-oncogene tyrosine-protein kinase ABL1; tyrosine-protein kinase ABL1; v-abl Abelson murine leukemia viral oncogene homolog 1; v-abl